A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Public ClinicalTrials.gov record NCT06920043. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Study identification
- NCT ID
- NCT06920043
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 42 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2025
- Primary completion
- Jul 9, 2028
- Completion
- Jul 9, 2028
- Last update posted
- Jul 7, 2026
2025 – 2028
United States locations
- U.S. sites
- 28
- U.S. states
- 10
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Chandler | Arizona | 85224 | Recruiting |
| GSK Investigational Site | Mesa | Arizona | 85381 | Recruiting |
| GSK Investigational Site | Tucson | Arizona | 85712 | Recruiting |
| GSK Investigational Site | Fresno | California | 93720 | Recruiting |
| GSK Investigational Site | Lancaster | California | 93534 | Recruiting |
| GSK Investigational Site | Pasadena | California | 91105 | Recruiting |
| GSK Investigational Site | Rialto | California | 92377 | Recruiting |
| GSK Investigational Site | Santa Maria | California | 93458 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33156 | Recruiting |
| GSK Investigational Site | Viera | Florida | 32940 | Recruiting |
| GSK Investigational Site | Marietta | Georgia | 30060 | Recruiting |
| GSK Investigational Site | Baltimore | Maryland | 21202 | Recruiting |
| GSK Investigational Site | Kansas City | Missouri | 64131 | Recruiting |
| GSK Investigational Site | New York | New York | 10029 | Recruiting |
| GSK Investigational Site | Fayetteville | North Carolina | 28304 | Recruiting |
| GSK Investigational Site | Wilson | North Carolina | 27612 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78745 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78757 | Recruiting |
| GSK Investigational Site | Dallas | Texas | 75203 | Recruiting |
| GSK Investigational Site | Georgetown | Texas | 78626 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77030 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77079 | Recruiting |
| GSK Investigational Site | Pasadena | Texas | 77505 | Recruiting |
| GSK Investigational Site | Pearland | Texas | 77584 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78215 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78229 | Recruiting |
| GSK Investigational Site | Waco | Texas | 76710 | Recruiting |
| GSK Investigational Site | Richmond | Virginia | 23249 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06920043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06920043 live on ClinicalTrials.gov.